B-cell lymphomas
Kite Pharma Inc. focuses extensively on relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, indolent non-Hodgkin lymphoma, mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma, and Richter transformation.
- Relapsed/refractory B-cell non-Hodgkin lymphoma
- First-line high-risk large B-cell lymphoma
- Follicular lymphoma
- Rare B-cell malignancies
The portfolio also includes studies in Waldenstrom macroglobulinemia and hairy cell leukemia, reflecting a strong interest in difficult-to-treat mature B-cell disorders.
Leukemia and lymphoid malignancies
The sponsor supports research in aggressive hematologic malignancies such as acute myeloid leukemia and B-precursor acute lymphoblastic leukemia, alongside broader work in pediatric and adult non-Hodgkin lymphoma.
- Acute myeloid leukemia
- Relapsed/refractory B-precursor acute lymphoblastic leukemia
- Pediatric and adolescent non-Hodgkin lymphoma
- Relapsed/refractory mantle cell lymphoma
These studies include both adult and pediatric populations, with attention to relapsed/refractory disease across multiple lymphoid and myeloid settings.
Plasma cell and myeloma research
Kite Pharma Inc. is also involved in relapsed/refractory multiple myeloma, including patients previously exposed to key standard therapies.
- Relapsed/refractory multiple myeloma
- Prior-line treated plasma cell malignancy
- Hematologic cancer resistance
This area extends the sponsor’s interest beyond B-cell lymphomas into plasma cell disorders and other advanced blood cancers.
Gene-modified cell therapy and long-term safety
Several trials examine gene-modified cells and their long-term use in hematologic cancers, with follow-up focused on safety in children, adolescents, and adults.
- Gene-modified cell therapy
- Long-term safety follow-up
- Pediatric and adolescent hematology
- Late-onset adverse events
Research includes monitoring for neurological disorders, autoimmune disorders, hematologic complications, serious infections, and new malignancies.
